{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:38:32Z","timestamp":1776778712318,"version":"3.51.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognostic value of longitudinal antinuclear antibody (ANA) dynamics in rheumatoid arthritis (RA) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine whether ANA development (titer rise\/seroconversion) is associated with 12-month clinical remission and to develop a prediction model for DAS28-CRP remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively enrolled 688 adults with RA (2010 criteria) from 2016\u20132023. ANA was assessed at baseline and 6 months (\u00b1\u00a02 months); development was defined as a \u22651-dilution increase or seroconversion (&amp;lt;1:80 to \u22651:80). The primary endpoint was DAS28-CRP remission at 12 months (&amp;lt;2.6); other endpoints were secondary\/exploratory. We used propensity score matching where appropriate. Multivariable logistic regression identified predictors, with performance assessed by AUC and calibration. Subgroup analyses distinguished seroconversion from titer elevation, and were stratified by baseline RF\/anti-CCP status. Sensitivity analyses used a higher positivity threshold (\u22651:160).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline ANA positivity was 63.7%, typically low titers (1:80, 1:160). Among 467 patients with serial ANA data, 94 (20.1%) exhibited ANA development, which was associated with significantly higher post-treatment disease activity and lower remission rates across multiple criteria (e.g., DAS28-CRP 43.8% vs 65.2%, p=0.004). In multivariable analysis, ANA development independently predicted non-remission (OR 0.472, p=0.010) together with baseline DAS28-CRP (OR 0.745, p=0.017). The prediction model achieved moderate discriminative ability, with an area under the curve (AUC) of 0.715 in the training cohort and 0.705 in the testing cohort, alongside acceptable calibration. Stratified analysis revealed that the negative prognostic value of ANA development was most pronounced in RF-negative patients (adjusted OR\u00a0=\u00a00.29, p=0.048). Intriguingly, baseline homogeneous ANA pattern was associated with higher remission rates (63.8% vs. 41.5% in pure speckled pattern, p&amp;lt;0.001). Sensitivity analysis using a \u22651:160 cutoff yielded distinct findings: high ANA titer was associated with a higher likelihood of remission (OR\u00a0=\u00a01.624, p=0.016).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rising ANA titers\/seroconversion during therapy are associated with reduced probability of DAS28-CRP remission at 12 months. The prognostic impact is modulated by baseline RF status, ANA fluorescence patterns, and the titer cutoff used. Conversely, a high baseline ANA titer (\u22651:160) itself may identify a subgroup with distinct characteristics. Incorporating ANA dynamics into routine monitoring may improve risk stratification and clinical decision-making in RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1743637","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:37:10Z","timestamp":1776775030000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of longitudinal antinuclear antibody dynamics in rheumatoid arthritis: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinyu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Department of Rheumatology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Bu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuesong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangjing","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-128-24465-4.00066-1","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100519","article-title":"Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data","volume":"23","author":"Scott","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex434","article-title":"Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far","volume":"57","author":"Jani","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042366","article-title":"Pharmacogenomics of anti-TNF treatment response marks a new era of tailored rheumatoid arthritis therapy","volume":"23","author":"Wysocki","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3809-0","article-title":"Meta-analysis: diagnostic accuracy of antibody against peptidylarginine deiminase 4 by ELISA for rheumatoid arthritis","volume":"36","author":"Ren","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080267","article-title":"Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity","volume":"67","author":"Halvorsen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2019-0167","article-title":"Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria","volume":"57","author":"Zhu","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00412","article-title":"Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014-2015","volume":"6","author":"Chan","year":"2015","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102400","article-title":"ANA as an entry criterion for the classification of SLE","volume":"18","author":"Pisetsky","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1177\/0961203316640920","article-title":"Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015","volume":"25","author":"Chan","year":"2016","journal-title":"Lupus"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1368088","article-title":"Relationship between autoimmune thyroid antibodies and anti-nuclear antibodies in general patients","volume":"15","author":"Ruan","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/ar3271","article-title":"Risk factors for ANA positivity in healthy persons","volume":"13","author":"Li","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5858\/2000-124-0071-gfcuot","article-title":"Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists","volume":"124","author":"Kavanaugh","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11271","article-title":"Exploring the role of antinuclear antibody positivity in the diagnosis, treatment, and health outcomes of patients with rheumatoid arthritis","volume":"3","author":"Paknikar","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s002960000073","article-title":"Clinical significance of low titer anti-nuclear antibodies in early rheumatoid arthritis: implications on the presentation and long-term course of the disease","volume":"20","author":"Caspi","year":"2001","journal-title":"Rheumatol Int"},{"key":"B18","article-title":"Radiological lesions of the hands in rheumatoid arthritis with rheumatoid factors and antinuclear antibodies","volume":"54","author":"Punzi","year":"1987","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/ar3546","article-title":"Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study","volume":"13","author":"Yukawa","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.02.003","article-title":"Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis","volume":"49","author":"Ishikawa","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-443-23947-2.00081-3","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.12.002","article-title":"Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing","volume":"15","author":"Fritzler","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243729","article-title":"Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis","volume":"15","author":"Mori","year":"2020","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2025.110610","article-title":"Autoantibody fine specificity restriction is associated with clinical response in RA treated with abatacept and methotrexate","volume":"282","author":"Brevet","year":"2026","journal-title":"Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11926-015-0500-9","article-title":"Antinuclear antibody (ANA) testing in patients treated with biological DMARDs: is it useful","volume":"17","author":"Garc\u00eda-De LaTorre","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1358114","article-title":"Association between serum antinuclear antibody and rheumatoid arthritis","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051553","article-title":"Clinical significance of antinuclear antibodies in patients with rheumatoid arthritis: from SETOUCHI-RA registry","volume":"14","author":"Nakano","year":"2025","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1361.100","article-title":"Autoimmunity and anti-TNF-alpha agents","volume":"1051","author":"Atzeni","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1743637\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:37:12Z","timestamp":1776775032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1743637\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1743637"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1743637","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1743637"}}